Dr. Carles Celma
![Person-Kymos-Carles-Celma Carles Celma](https://kymos.com/wp-content/uploads/2021/08/Person-Kymos-Calres-Celma.jpg)
- Scientific Director at Kymos
- Active in Drug research and development for over 30 years
- Extensive experience in Mass Spectrometry
- Expert in biologics and biosimilars
- Wide experience in method development, validation and sample analysis using physicochemical, binding and cellular methods for regulated analysis
Experience
While working on his PhD at University, Carles Celma was responsible of the Mass Spectrometry Facility at the Chemistry Faculty.
He then started to work for Ipsen as Head of Mass Spectrometry in 1990 and left in 2012 as the Director of Bioanalysis. That year, Celma joined Kymos as Biologics Scientific Director.
Expertise
Dr. Carles Celma has more than 40 communications to congresses and 10 publications in different international journals (see list of publications). In addition, he publishes regularly on Kymos’ webpage.
Education
Celma graduated 1981 from the University of Barcelona with a degree in Organic Chemistry and acquired 1990 a PhD in Organic Chemistry.
Want to get to know him better?
Read about him on researchgate.
List of publications:
- Celma and E. Giralt, “Optimization of the Experimental Procedures in Fast Atom Bombardment Mass Spectrometry of Peptides with a Quadrupole Mass Spectrometer”, Biomed. Mass Spectrom., 1990, 19, 235‑239.
- Celma and E. Giralt, “Determination of the Enantiomeric Purity of Synthetic Peptides by Gas Chromatography‑Mass Spectrometry”, J. Chromatogr. Biomed. Applications, 1991, 562, 447‑458.
- “Convergent Solid Phase Peptide Synthesis IX: Application to the Synthesis of Peptides with Repetitive Sequences”, C. Celma, F. Albericio, E. Pedroso and E. Giralt., Peptide Research, 5, 62‑70, (1992).
- Celma, “Determination of the aza alkyl lysophospholipid 3-methoxy 2-N,N-methyloctadecyl amino propyloxy-phosphoryl choline in rat plasma by liquid chromatography particle beam mass spectrometry”, J. Chromatogr. Biomed. Applications, 1993, 622, 215-222.
- Celma, “Determination of the Platelet activating factor antagonist 6-(2-chlorophenyl)-9-[(4-methoxy phenyl)thio carbamoyl]-1- methyl-7,8,9,10-tetra hydro-4H-pyrido [4′,3′- 4,5] – Thieno [3,2-f][1,2,4,]triazolo [4,3-a][1,4] diazepine in human plasma by liquid chromatography – thermospray mass spectrometry”, J. Chromatography B, 1994, 657, 214-218.
- Celma, “Mass Spectrometry and Liquid Chromatography / Mass Spectrometry of Some Derivates of 6-(2-chlorophenyl)-1-methyl-7,8,9,10-tetra hydro-4H-pyrido [4′,3′- 4,5] – Thieno [3,2-f][1,2,4,]triazolo [4,3-a][1,4] diazepines”. Biological Mass Spectrometry, 1994, 23, 13-19.
- Celma, J.A. Allué, J. Pruñonosa, C. Peraire, R. Obach, “Determination of N-Acetylcysteine in human plasma by liquid chromatography coupled to tandem mass spectrometry”, J. Chromatography A, 2000, 870, 13-22.
- Celma, J.A. Allué, J. Pruñonosa, C. Peraire, R. Obach. “Simultaneous determination of paracetamol and chlorpheniramine in human plasma by liquid chromatography – tandem mass spectrometry”. J. Chromatography A, 2000, 870, 77-86.
- Ventura, J. Solà, C. Celma, C. Peraire and R. Obach, “In Vitro Metabolism of Irosustat, A Novel Steroid Sulphatase Inhibitor: Inter-Species Comparison, Metabolite Identification and Metabolic Enzyme Identification”, Drug Metabolism and Disposition, 2011, 39, 1235-1246.
- Morte C, Celma C, De Geyter C, Urbancsek J, Coroleu Lletget B, Cometti B. Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation. Am J Reprod Immunol. 2017 Sep;78(3).
Extractables & Leachables: Analysis, Study Design and ICH Q3E Guideline
When developing and releasing pharmaceutical products to the market, ensuring their safety and efficacy is of critical importance. Determining the impurity profile is a must, and a vital part of it is the analysis and (...) Read more
Transdermal Testing: Analysis and Quality Control of Transdermal Patches
Transdermal patches, or Transdermal Drug Delivery Systems (TDDS), are designed to deliver active substances through the skin directly into the bloodstream at a prolonged and constant rate. Due to their unique attributes, they present different (...) Read more
Stability Testing: What’s to come in 2024
Stability testing is an essential part of drug development as it ensures the efficacy and safety of the medicinal product throughout its shelf life. It allows the evaluation of APIs and drug product stability under (...) Read more
Liraglutide & Semaglutide: Exploring Biosimilar Studies for GLP-1 receptor agonists
Liraglutide and Semaglutide have become key players in the pharmaceutical and healthcare industry as they are both being used and have been approved not only as an anti-diabetic medication but also as an obesity and (...) Read more
Impurity Profiling: Characterization of unknown impurities in pharmaceuticals
Characterization of unknown impurities found in pharmaceutical substances and pharmaceutical products is a vital part of the regulatory approval process. According to ICH guidelines, if the estimation indicates an impurity content higher than 0.1%, it (...) Read more
U-Shape and Lean Lab: Improving productivity in the laboratory
The landscape of the life sciences ecosystem is ever-changing, and laboratory operations continually adapt to meet market demands, with efficiency and productivity crucial to the industry's evolution. Among the key drivers of this transformation are (...) Read more
KOREA PHARM & BIO: Goyang, KR | 23-26 Apr 2024
BIO KOREA 2024: Seoul, KR | 08-10 May 2024
BIO International Convention: San Diego, US | 3-6 Jun 2024
Congrès POLEPHARMA Biotesting: Évreux, FR | 5-6 Jun 2024
AFI Symposium: Rimini, IT | 5-7 Jun 2024
BIOPLUS – INTERPHEX KOREA: Seoul, KR | 10-12 Jul 2024
Farmaforum: Madrid, ES | 25-26 Sep 2024
Biomarkers Europe 2024: Basel, CH | 30 Sep – 01 Oct 2024
CPHI 2024: Milan, IT | 8-10 Oct 2024
BIO-Europe Autumn: Stockholm, SE | 4-6 Nov 2024
European Bioanalysis Forum: Barcelona, ES | 20-22 Nov 2024
PharmaLab Congress: Düsseldorf, DE | 25-27 Nov 2024
I4ID 2024: Lyon, FR | 27-28 Nov 2024